OIM
Oracle Investment Management Portfolio holdings
AUM
$116M
This Quarter Return
+34.09%
1 Year Return
+84.31%
3 Year Return
+539.5%
5 Year Return
+791.07%
10 Year Return
+13,222.09%
AUM
$125M
AUM Growth
+$125M
(+34%)
Cap. Flow
+$1.34M
Cap. Flow
% of AUM
1.07%
Top 10 Holdings %
Top 10 Hldgs %
97.68%
Holding
19
New
1
Increased
4
Reduced
4
Closed
2
Top Buys
| 1 |
Phathom Pharmaceuticals
PHAT
|
$9.48M |
| 2 |
Myriad Genetics
MYGN
|
$2.04M |
| 3 |
Palantir
PLTR
|
$1.02M |
| 4 |
Pacific Biosciences
PACB
|
$518K |
| 5 |
Biohaven
BHVN
|
$240K |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$6.38M |
| 2 |
GeneDx Holdings
WGS
|
$2.55M |
| 3 |
EyePoint Pharmaceuticals
EYPT
|
$1.59M |
| 4 |
Ardelyx
ARDX
|
$819K |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
$333K |
Sector Composition
| 1 | Healthcare | 97.34% |
| 2 | Consumer Discretionary | 1.84% |
| 3 | Technology | 0.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GeneDx Holdings
WGS
$3.72B
| $44.4M | 26.6% | 1,045,768 -60,000 | -5% | -$2.55M |
|
|
2
Biohaven
BHVN
$1.63B
| $35.2M | 21.12% | 705,250 +4,800 | +0.7% | +$240K |
|
|
3
Phathom Pharmaceuticals
PHAT
$864M
| $13.6M | 8.12% | 749,487 +524,487 | +233% | +$9.48M |
|
|
4
Ardelyx
ARDX
$1.53B
| $9.43M | 5.65% | 1,369,200 -118,931 | -8% | -$819K |
|
5
QuidelOrtho
QDEL
$1.95B
| $5.39M | 3.23% | 118,291 | – | – |
|
6
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.07M | 2.44% | 535,558 | – | – |
|
|
7
Myriad Genetics
MYGN
$593M
| $3.68M | 2.21% | 134,500 +74,500 | +124% | +$2.04M |
|
8
Forian
FORA
$61.3M
| $2.93M | 1.76% | 1,356,107 | – | – |
|
9
CAVA Group
CAVA
$7.83B
| $2.3M | 1.38% | 18,600 | – | – |
|
|
10
Pacific Biosciences
PACB
$393M
| $1.24M | 0.74% | 727,877 +304,739 | +72% | +$518K |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $1.1M | 0.66% | 34,200 -199,000 | -85% | -$6.38M |
|
|
12
Palantir
PLTR
$372B
| $1.02M | 0.61% | +27,500 | New | +$1.02M |
|
13
Biogen
BIIB
$19.4B
| $468K | 0.28% | 2,412 | – | – |
|
|
14
EyePoint Pharmaceuticals
EYPT
$797M
| $260K | 0.16% | 32,500 -199,357 | -86% | -$1.59M |
|
15
Biodesix
BDSX
$62.6M
| $51.5K | 0.03% | 28,916 | – | – |
|
|
AGEN
16
Agenus
AGEN
$133M
| – | – | -17,500 | Closed | -$293K |
|
17
Novavax
NVAX
$1.21B
| – | – | 0 | – | – |
|
|
WBA
18
DELISTED
Walgreens Boots Alliance
WBA
| – | – | -27,500 | Closed | -$333K |
|
19
SPDR NYSE Technology ETF
XNTK
$1.25B
| – | – | 0 | – | – |
|